• PrSandoz® Semaglutide, a generic version of PrOzempic®, approved for the treatment of adult patients with type 2 diabetes
  • This lower-cost alternative supports improved affordability and access to type 2 diabetes treatments across Canada
  • An important milestone in further strengthening Sandoz Canada's established diabetes portfolio

SAINT-HUBERT, QC, Sept. 18, 2026 /CNW/ -- Sandoz Canada Inc. today announces that Health Canada has granted authorization to market PrSandoz® Semaglutide, a generic version of Novo Nordisk's PrOzempic®, bringing Canadian patients one step closer to greater access. PrSandoz® Semaglutide has been approved for the once-weekly treatment of adult patients with type 2 diabetes to improve glycemic control, in combination with lifestyle changes and other antidiabetic agents1.

The generic version of semaglutide is a complex synthetic product that is pharmaceutically equivalent to the brand name biologic drug. The Notice of Compliance was issued for three doses delivered subcutaneously via two pen presentations: a pen delivering 0.25 mg or 0.5 mg doses (containing 2 mg of semaglutide [1.34 mg/mL]), and a pen delivering 1 mg doses (containing 4 mg of semaglutide [1.34 mg/mL]).